Target intelligence / Profile preview

THO complex subunit 4 (ALYREF)

Target
ALYREF
Molecular classification
mRNA export adapter, Component of the Transcription and Export (TREX) complex, RNA recognition motif (RRM)-containing protein, Other
01

Overview

THO complex subunit 4 (ALYREF) is a nuclear RNA-binding protein acting as a key mRNA export adapter. It is an integral part of the TREX complex, which couples mRNA transcription, processing, and export from the nucleus[1][4]. ALYREF directly interacts with the nuclear cap binding complex (CBC) via its RNA recognition motif (RRM), facilitating the recruitment of mRNA export machinery to the 5' cap of nascent transcripts[1][2][3]. This step is essential for proper mRNA export and RNA metabolism in eukaryotes. ALYREF also mediates interactions with the export receptor NXF1-NXT1 and is a target for viral proteins that hijack export pathways. Disruption of ALYREF or its interactions, such as by mutations, is associated with various pathologies, including cancer, where it can be upregulated and contribute to disease progression[1][2]. No small molecule drugs are known to target ALYREF as of current literature.

Other names
ALYBEFTHOC4Tho4REFAly/REF export factorTranscriptional coactivator Aly/REFbZIP-enhancing factor BEFAlly of AML-1 and LEF-1THO complex 4tho4THO complex subunit 4, ALYREF, ALY, BEF, THOC4
02

Mechanism of action

Not applicable for drugs (as no drugs are reported to target ALYREF directly). Viral proteins such as HSV-1 ICP27 and HVS ORF57 interact with the RRM domain of ALYREF to hijack mRNA export machinery.

03

Biological functions

Nuclear export of mRNACoupling mRNA transcription, processing, and exportInteraction with nuclear cap binding complex (CBC)Linkage of TREX complex to mRNA 5' capDirect interaction with mRNA export receptor NXF1-NXT1RNA metabolismInvolvement in splicing and polyadenylation
04

Disease associations

Cancer (frequently upregulated in cancerous tissues, and mutations affecting its interaction may contribute to pathogenesis)Other (potential viral infection pathways via viral proteins that target ALYREF to hijack export machinery)
05

Safety considerations

Targeting ALYREF could disrupt global mRNA export, possibly leading to broad cellular dysfunction and toxicityPotential impact on normal cell viability and gene expression, given ALYREF’s central role in mRNA metabolism.
06

Biomarkers

ALYREF expression upregulation may serve as a biomarker for certain cancersMutations in interface residues (e.g., K330N in NCBP1, R105C in NCBP2) disrupting interaction with ALYREF may correlate with disease

Beyond the preview

Go deeper on THO complex subunit 4 (ALYREF).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on THO complex subunit 4 (ALYREF).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call